From the MM board a must read
Scientific Observations on HPB84 and HCCF
--------------------------------------------------------------------------------
Greetings.
My name is Mike, and, because I am a scientist, I felt the need to throw my two cents in regarding the debate about the future of HPB84. I have to say that I am not a financial expert, nor am I very good at reading charts or leveraging probability waves. My approach to this stock was rather clinical and mundane. As soon as I saw the ingredient list, I did some scientific research into the efficacy of the compounds used in the treatment, found a wealth of scientific studies to support the antidiabetic action of each one of the seven major ingredients individually, and then I immediately bought and held.
Why did I buy and hold? Because, I immediately knew the inevitable outcome of any major clinical trial, done correctly, would be a success. How did I know this? Because I found dozens of clinical studies in the U.S. NIH (National Institute of Health) National Library of Medicine database, performed my multiple stellar medical establishments, which supports the direct antidiabetic action of each of the seven major ingredients separately. That implies that a synergystic combination of them all should prove more effective, at far lower doses than those cited in the studies.
Why would this be true? Well, those who understand the pharmacology of drug interactions also understand the "multiplicative" principle. What does this mean? The means that if Valium, for example, provides 3 "units" of sedation, and Xanax provides 5 "units" of sedation, then the total sedation you get from taking a Valium and a Xanax is not 3 + 5, or 8 units of sedative activity, but more like 3 TIMES 5, or 15 units of sedative activity. That is why it can be dangerous to mix drugs with similar pharmacokinesis, i.e., precisely due to this synergistic effect.
What does this mean for HPB84? It means that, because there are so many different phytochemicals with similar action within the product, each of which is clinically proven to be quite bioactive by itself, that the amount of each required in combination compared to the amounts cited in sole-use studies, should be remarkably lower. Although admittedly, there's no way of knowing how much lower, and each individual patient may be quite different.
Dose-response curve aside, the point is, that even though the synergistic combination may not have been tested yet, each individual ingredient in HPB84 HAS been successfully clinically tested by itself, therefore, while non-scientific personnel continue to run around like chickens with their heads cut off, worrying about the outcome of clinical trials, I was able to base my buying decision solidly on the prescient foreknowledge that the clinical trial, if conducted with a proper scientific method, CANNOT FAIL, precisely because the clinical trials of the individual indgredients have not failed. Therefore the product cannot fail. That, in conjunction with the enormous market, is a sure prescription for success.
Although there are dozens of clinical trials in the literature for each major ingredient, I have taken the liberty of compiling a list of abstracts including only one trial for each ingredient in the product, for the sake of brevity, which clinically validates its efficacy as an antidiabetic therapy. Some of the substances are even being fast-tracked into pharmaceutical production as we speak, because of their remarkable effectiveness. So, although I initially had doubts about the product being herbal in nature, I was able to remove all personal doubt after doing a proper literature search, and examining the studies below, as well as the many others which I have not listed.
Now, placing my "chemist" hat on, the only concern I had after the question of clinical effectiveness, was the integrity of the raw materials. My original understanding was that the raw materials were being imported from overseas, and it was unclear whether or not they were being assayed prior to manufacturing the product. However, recent press releases have put that issue to rest, stating that the raw materials are assayed for authenticity and potency before inclusion into the product. That statement, to those who understand pharmacology, was more important than all of the other PRs released to date.
I invite the members of this forum to read the abstracts of the clinical studies below, for themselves. I always smile when I read about people buying or selling on a knee-jerk response to some daily happenstance, whatever that may be. I smile, because I know medical science doesn't work that way. A given therapy is either scientifically valid and clinically effective, or it's not. Once in vivo effectiveness has been confirmed through double-blind trials, the hard part is over! And regardless of emotions or personal conjectures, I believe any rational fact-finder would agree, after reviewing the literature in the scientifc record, that the basis for this product is scientifically valid, and the product is clinically effective, namely because the sum of its parts has been shown to be. I invite readers to review these studies for yourselves, and draw your own conclusions.
So, if the product can't fail, then the only thing that could possibly go wrong, is corporate governance. But as a scientific professional, I think that if this company really has the slightest clue as to exactly what they have here (which I believe they do), and its multimillion-dollar potential market, that there'd be no way they would be so short sighted as to loot the company at this early stage. Similarly, I think it is trememdously myopic of investors to sell this stock short and risk being cut out of the major price gain, just to gain a few extra shares, or a measly few thousand dollars profit. This product has the potential to make us all very very rich, well into the six or seven figure range, and once investors get ahold of that and really understand the science behind the ingredients in the product, you will begin to see an immediate upswing in the stock price, as people panic to take advantage of bargain lows.
In my opinion, if the corporoate governance does fail because the company is diluting on every price gain, then the real tragedy will not be the loss of my measly few thousand dollars. I can always make that back. The real tragedy will be the loss to those who are in dire medical need of the product, who will not be able to obtain it, if the business fails. Furthermore, I also feel the company has an ethical responsibility to market this product at a price point which enables lower-middle class diabetics, who are poor, to have some way of obtaining the product. After all, when you are in the business of medicine, it's not just about dollars and cents, its about preserving human life, and human quality of life.
So, thank you for reading, and the bibliography of studies will appear in the following post.
